Cargando…

Naldemedine-induced Opioid Withdrawal Syndrome in a Patient with Breast Cancer without Brain Metastasis

Opioid-induced-constipation (OIC) can be treated by naldemedine and other peripherally acting mu-opioid receptor antagonists (PAMORA) via a novel mechanism. We describe the case of a 52-year-old female outpatient who developed OIC while receiving oxycodone for pain due to cancer with multiple bone m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishii, Koji, Yamashita, Haruna, Yamaguchi, Midori, Komatsu, Yuya, Ryu, Emi, Morishita, Satoru, Matsuo, Kumi, Kamada, Masatsugu, Ikeda, Tsunako, Ashizawa, Kazuto, Hara, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008055/ https://www.ncbi.nlm.nih.gov/pubmed/31534081 http://dx.doi.org/10.2169/internalmedicine.3098-19

Ejemplares similares

Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies
por: Saito, Yoji, et al.
Publicado: (2018)

Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain
por: BouSaba, Joelle, et al.
Publicado: (2022)

Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial
por: Ozaki, Anna, et al.
Publicado: (2022)

Naldemedine: A New Option for OIBD
por: Coluzzi, Flaminia, et al.
Publicado: (2020)

A retrospective study of the efficacy and safety of naldemedine for opioid‐induced constipation in thoracic cancer patients
por: Imai, Hisao, et al.
Publicado: (2022)

Pharmacologic effects of naldemedine, a peripherally acting μ‐opioid receptor antagonist, in in vitro and in vivo models of opioid‐induced constipation
por: Kanemasa, Toshiyuki, et al.
Publicado: (2019)

Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study
por: Takagi, Yusuke, et al.
Publicado: (2020)

Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis
por: Kanbayashi, Yuko, et al.
Publicado: (2022)

Population Pharmacokinetics and Exposure-Response Relationships of Naldemedine
por: Kubota, Ryuji, et al.
Publicado: (2018)

Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan
por: Takata, Keiko, et al.
Publicado: (2022)

A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer
por: Kamiya, Teruhiko, et al.
Publicado: (2023)

Fentanyl/naldemedine: Diarrhoea and decreased peristalsis: case report
Publicado: (2021)

Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer
por: Katakami, N, et al.
Publicado: (2018)

Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy
por: Stern, Emily K, et al.
Publicado: (2018)

Opioid therapy duration before naldemedine treatment is a significant independent risk of diarrhea: a retrospective cohort study
por: Okamoto, Akiharu, et al.
Publicado: (2021)

Efficacy and Safety of Naldemedine for Patients with Cancer with Opioid-Induced Constipation in Clinical Practice: A Real-World Retrospective Study
por: Nishiba, Hiromi, et al.
Publicado: (2022)

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine
por: Fukumura, Kazuya, et al.
Publicado: (2019)

Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies
por: Osaka, Iwao, et al.
Publicado: (2019)

A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy
por: Webster, Lynn R, et al.
Publicado: (2020)

Rationale and design of a multicenter, double-blinded, randomized, placebo-controlled trial to investigate the effects of naldemedine on opioid-induced constipation for patients with cancer pain: A study protocol
por: Higashibata, Takahiro, et al.
Publicado: (2022)

Is this ‘complicated’ opioid withdrawal?
por: Parkar, S.R., et al.
Publicado: (2006)

Naldemedine is effective in the treatment of opioid-induced constipation in patients with chronic non-cancer pain who had a poor response to laxatives
por: Hale, Martin E., et al.
Publicado: (2021)

Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies
por: Camilleri, Michael, et al.
Publicado: (2021)

Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age
por: Wild, James, et al.
Publicado: (2020)

Real-World Patient Characteristics and Treatment Patterns of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Cancer: A Multicenter Retrospective Chart Review Study
por: Hiruta, Eriko, et al.
Publicado: (2021)

Fentanyl withdrawal: Iatrogenic opioid withdrawal syndrome: case report
Publicado: (2022)

Tracheal Paraganglioma: A Case report and Review of the Pertinent Literature
por: Kamada, Masatsugu, et al.
Publicado: (2021)

Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials
por: Wild, James, et al.
Publicado: (2019)

Alleviating Symptoms of Withdrawal from an Opioid
por: Wakim, Judith H.
Publicado: (2012)

Nonpharmacological Modality of Treating Opioid Withdrawal
por: Nair, Abhijit S
Publicado: (2019)

The Role of Lofexidine in Management of Opioid Withdrawal
por: Pergolizzi, Joseph V., et al.
Publicado: (2018)

Operational definition of precipitated opioid withdrawal
por: Dunn, Kelly E., et al.
Publicado: (2023)

Concurrent opioid and alcohol withdrawal management
por: Colvard, Michelle
Publicado: (2023)

Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study
por: Ozaki, Anna, et al.
Publicado: (2020)

Opioid withdrawal behavior in spiny mice: A novel preclinical model of neonatal opioid withdrawal syndrome (NOWS)
por: Stevens, Sarah, et al.
Publicado: (2021)

Neuroplasticity of the extended amygdala in opioid withdrawal and prolonged opioid abstinence
por: Kaplan, Gary B., et al.
Publicado: (2023)

Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study
por: Webster, Lynn R., et al.
Publicado: (2018)

Real-World Evidence for the Safety and Effectiveness of Naldemedine in the Management of Opioid-Induced Constipation in Patients With Cancer Pain: Post-hoc Subgroup Analysis of Post-marketing Surveillance in Japan
por: Naya, Noriyuki, et al.
Publicado: (2023)

Identification and Treatment of Opioid Withdrawal and Opioid Use Disorder in the Emergency Department
por: Jennings, Lindsey, et al.
Publicado: (2020)

A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain
por: Webster, Lynn R, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h0g5pfhoge5p2q42bnlkhsn7hs